Meg Spencer, CEO of laser manufacturer Hamilton Thorne Ltd., on how the company stays on the cutting edge of life science technology and its footprint in stem cells and regenerative medicine.

Laser-based lab equipment maker Hamilton Thorne Inc. (CVE:HTL) derives a major part of its revenues from the life sciences R&D market. CEO Meg Spencer says that requires the company to surf the leading edge of several life science research waves, including stem cells and regenerative medicine.

The Beverly, Mass.-based company looks to help solve some of the problems scientists encounter as they develop their research on stem cells into regenerative medicine techniques. Those often involve the growth of millions — or even billions — of cells, so anything that can accelerate or automate that process is vital to innovation in the space.

Attachments:
FileDescriptionFile size
Download this file (39229933_12-08-2015-10.51.15.mp3)39229933_12-08-2015-10.51.15.mp3MassDevice Podcast1916 kB

Subscribe to Our Investor Email List